Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis

Figure 6

In vivo efficacies of ES-based fusion proteins and the enediyne-energized fusion proteins on PG-BE1 xenograft models. In experiment 1 (Exp 1), nude mice bearing human lung carcinoma PG-BE1 xenografts were treated with ES, ES-LDP or LDP-ES i.p. injections at different doses (nā€‰=ā€‰6). Mean tumor volumes (A) and mean body weights of mice (C) in each group are shown. Arrows indicate the day of injection (every other day). In experiment 2 (Exp 2), nude mice bearing PG-BE1 xenografts were treated with LDM, LDP-ES-AE, or ES-LDP-AE (nā€‰=ā€‰6), i.v. injections respectively. Mean tumor volumes (B) and mean body weights of mice (D) in each group are shown. Arrows indicate the day of injection (day 9 and 15).

Back to article page